靶向治疗携带 BRAF V600E 突变的颅咽管瘤。
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
机构信息
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Divisions of Neuro-Oncology and Hematology/Oncology, Departments of Neurology and Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Cancer. 2019 Sep 1;125(17):2910-2914. doi: 10.1002/cncr.32197. Epub 2019 Jul 17.
Abstract
Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors for patients with PCPs. With continued successful responses, it is proposed that BRAF (and MEK) inhibitors be evaluated for the neoadjuvant treatment of patients with PCPs.
摘要
乳头型颅咽管瘤（PCP）的特征是存在 BRAF V600E 突变，该突变正成为诊断和治疗决策的有用指导。正在进行的多中心联盟 A071601 二期试验正在评估 BRAF 和丝裂原活化蛋白激酶激酶（MEK）抑制剂对 PCP 患者的疗效。随着持续成功的反应，提议评估 BRAF（和 MEK）抑制剂作为 PCP 患者的新辅助治疗。
相似文献
1
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.靶向治疗携带 BRAF V600E 突变的颅咽管瘤。
Cancer. 2019 Sep 1;125(17):2910-2914. doi: 10.1002/cncr.32197. Epub 2019 Jul 17.
2
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.BRAF V600E突变型乳头状颅咽管瘤对靶向治疗的显著反应
J Natl Cancer Inst. 2015 Oct 23;108(2). doi: 10.1093/jnci/djv310. Print 2016 Feb.
3
Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.病例报告和文献复习：BRAF-V600 抑制剂治疗颅咽管瘤：一种潜在的治疗范式转变。
J Clin Pharm Ther. 2022 Jun;47(6):826-831. doi: 10.1111/jcpt.13600. Epub 2022 Jan 12.
4
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.BRAF-V600E 突变型乳头状颅咽管瘤对 BRAF 和 MEK 抑制剂联合治疗反应显著。
CNS Oncol. 2017 Apr;6(2):95-99. doi: 10.2217/cns-2016-0034.
5
Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.BRAF 突变型侵袭性颅咽管瘤的靶向治疗：病例报告及文献复习。
J Endocrinol Invest. 2024 Nov;47(11):2835-2842. doi: 10.1007/s40618-024-02382-7. Epub 2024 May 2.
6
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.采用新辅助靶向治疗的BRAFV600E突变复发性乳头状颅咽管瘤。
Acta Neurochir (Wien). 2017 Nov;159(11):2217-2221. doi: 10.1007/s00701-017-3311-0. Epub 2017 Sep 16.
7
BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study.BRAF 和 MEK 抑制剂靶向治疗颅咽管瘤：一项队列研究。
Eur J Endocrinol. 2024 Aug 5;191(2):251-261. doi: 10.1093/ejendo/lvae091.
8
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.乳头型颅咽管瘤对BRAF抑制剂维莫非尼治疗有明显反应。
Pituitary. 2016 Oct;19(5):544-6. doi: 10.1007/s11102-015-0663-4.
9
Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.病例报告：BRAF/MEK 抑制剂在侵袭性 BRAF 突变型颅咽管瘤中的成功应用。
World Neurosurg. 2023 Dec;180:e117-e126. doi: 10.1016/j.wneu.2023.08.137. Epub 2023 Sep 6.
10
Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.BRAF V600E 突变型颅咽管瘤对 vemurafenib 和 cobimetinib 治疗有良好反应：病例报告及文献复习。
CNS Oncol. 2024 Jan 1;13(1):CNS106. doi: 10.2217/cns-2023-0018. Epub 2024 Feb 13.
引用本文的文献
1
Comparative analysis of clinical features, methylation and immune microenvironment in pediatric and adult papillary craniopharyngiomas: results from a multicenter study.儿童和成人乳头状颅咽管瘤的临床特征、甲基化及免疫微环境的比较分析：一项多中心研究结果
Sci Rep. 2025 Jul 28;15(1):27422. doi: 10.1038/s41598-025-12662-8.
2
Targeted therapy of papillary craniopharyngioma.乳头状颅咽管瘤的靶向治疗
Med Oncol. 2025 Jul 22;42(8):367. doi: 10.1007/s12032-025-02920-0.
3
Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.颅咽管瘤病理生理学的最新进展及新兴治疗方法
Front Endocrinol (Lausanne). 2025 May 13;16:1562942. doi: 10.3389/fendo.2025.1562942. eCollection 2025.
4
Revisiting the combined approach of Yaşargil for microsurgical removal of intra-extraventricular and pure intraventricular craniopharyngiomas.重新审视亚萨吉尔用于显微手术切除脑室内外及单纯脑室内颅咽管瘤的联合方法。
Acta Neurochir (Wien). 2025 May 23;167(1):149. doi: 10.1007/s00701-025-06560-1.
5
Endoscopic Endonasal Approach for Residual and Recurrent Craniopharyngioma after Transcranial Approach: A Multi-institutional Experience.经鼻内镜入路治疗经颅手术后残留及复发性颅咽管瘤：多机构经验
J Neurol Surg B Skull Base. 2024 May 3;86(3):295-302. doi: 10.1055/a-2301-3867. eCollection 2025 Jun.
6
Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm.颅咽管瘤的现代治疗以改善预后：治疗模式转变的证据
Endocrine. 2025 May 10. doi: 10.1007/s12020-025-04216-9.
7
Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review.BRAF V600E 突变的乳头状颅咽管瘤中 BRAF/MEK 抑制剂疗法的前景：一项范围综述
Neurol Med Chir (Tokyo). 2025 May 15;65(5):217-229. doi: 10.2176/jns-nmc.2024-0246. Epub 2025 Mar 21.
8
The spectrum of radiation therapy options for craniopharyngioma: a systematic review.颅咽管瘤放射治疗选择的范围：一项系统评价
J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-05001-4.
9
Current clinical trials for craniopharyngiomas: what's on the horizon?颅咽管瘤的当前临床试验：未来前景如何？
J Neurooncol. 2025 Apr;172(2):281-288. doi: 10.1007/s11060-024-04899-6. Epub 2025 Mar 5.
10
Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.安罗替尼可能对无BRAFv600e突变的乳头状颅咽管瘤具有治疗作用。
Acta Neuropathol Commun. 2025 Mar 3;13(1):46. doi: 10.1186/s40478-025-01972-7.
本文引用的文献
1
A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.一种用于术前预测颅咽管瘤 BRAF 突变状态的临床规则。
Neurosurgery. 2019 Aug 1;85(2):204-210. doi: 10.1093/neuros/nyy569.
2
Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report.用达拉非尼治疗的伴有BRAF V600E突变的复发性乳头状颅咽管瘤：病例报告
J Neurosurg. 2018 Apr 27;130(4):1299-1303. doi: 10.3171/2017.11.JNS172373. Print 2019 Apr 1.
3
Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.拉克氏裂囊肿作为小儿乳头状颅咽管瘤的起源
Front Genet. 2018 Feb 22;9:49. doi: 10.3389/fgene.2018.00049. eCollection 2018.
4
Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.利用磁共振成像特征预测颅咽管瘤的 BRAF 突变状态。
J Neurosurg. 2018 Jul;129(1):27-34. doi: 10.3171/2017.4.JNS163113. Epub 2017 Oct 6.
5
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.采用新辅助靶向治疗的BRAFV600E突变复发性乳头状颅咽管瘤。
Acta Neurochir (Wien). 2017 Nov;159(11):2217-2221. doi: 10.1007/s00701-017-3311-0. Epub 2017 Sep 16.
6
Do craniopharyngioma molecular signatures correlate with clinical characteristics?颅咽管瘤分子特征与临床特征相关吗？
J Neurosurg. 2018 May;128(5):1473-1478. doi: 10.3171/2017.1.JNS162232. Epub 2017 Jul 14.
7
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.BRAF-V600E 突变型乳头状颅咽管瘤对 BRAF 和 MEK 抑制剂联合治疗反应显著。
CNS Oncol. 2017 Apr;6(2):95-99. doi: 10.2217/cns-2016-0034.
8
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.维莫非尼用于放射性碘难治性BRAF（V600E）阳性转移性或不可切除性乳头状甲状腺癌患者：一项非随机、多中心、开放标签的2期试验。
Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.
9
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.造釉细胞瘤型和乳头型颅咽管瘤的特征是具有明显的表观基因组以及突变和转录组特征。
Acta Neuropathol Commun. 2016 Feb 29;4:20. doi: 10.1186/s40478-016-0287-6.
10
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.BRAF V600E突变型乳头状颅咽管瘤对靶向治疗的显著反应
J Natl Cancer Inst. 2015 Oct 23;108(2). doi: 10.1093/jnci/djv310. Print 2016 Feb.
Zotero 插件